Taiwan Liposome Sees Generic Of J&J Cancer Drug In Europe Next Year
This article was originally published in PharmAsia News
Executive Summary
Taiwan Liposome said it expects its Doxisome (liposomal) generic of a treatment for breast and ovarian cancer to be on Europe's $200 million market within the next nine months and then the larger U.S. market.